Australian researchers identify a link between itchy skin and gut pain, caused by identical receptors
This is big news for Irritable Bowel Syndrome (IBS) patients: 11 percent of the world’s population suffers from IBS, but the fight against chronic pain has taken a major step forward with scientists identifying receptors in the nervous system which cause the condition in the hope of developing effective treatments.
Flinders University researchers at SAHMRI have discovered receptors that cause itchy skin also exist in the human gut and activate neurons, which result in IBS patients feeling like they’re experiencing chronic gut pain or a seriously painful ‘gut itch.’
In millions of Americans with IBS, it looks like these ‘itch’ receptors might be more present than in healthy people. This means that more neurons are activated, causing the feeling of more pain.
NHMRC and Matthew Flinders Research Fellow in Gastrointestinal Neuroscience, Professor Stuart Brierley, says these gut itch receptors could offer a new way of targeting the underlying cause of gut pain, rather than using traditional drugs (like opioids), which don’t fix the problem right now.
“We found receptors which bring about an itchy feeling on skin also do the same in in the gut, so these patients are essentially suffering from a ‘gut itch’. We’ve translated these results to human tissue tests and now hope to help create a treatment where people can take an oral medication for IBS.”
“Patients with IBS suffer from chronic abdominal pain and experience rewiring of their nervous system so they feel pain when they shouldn’t – we decided to ask important questions about how nerves in the gut are activated to cause pain in order to seek out potential solutions.”
Professor Brierley, also the Director of the Visceral Pain Research Group at SAHMRI, says pain experienced by IBS sufferers takes place when itch receptors are coupled with what’s known as the ‘wasabi receptor’ in the nervous system, which normally helps people react to consuming wasabi- the Japanese condiment.
“If you think about what happens when you eat wasabi, it activates a receptor on the nerves and sends a pain signal – that’s exactly what’s happening within in their gut as they experience an itchy effect or wasabi effect in the gut.”
“Having shown these mechanisms contribute to chronic gut pain, we can now work out ways to block these receptors and thereby stop the ‘gut itch’ signal traveling from the gut to the brain. This will be a far better solution that the problems currently presented by opioid treatments”.
The Latest on: irritable bowel syndrome
via Google News
The Latest on: Irritable bowel syndrome
- Fighting intestinal infections with the body's own endocannabinoidson October 7, 2020 at 8:03 am
Endocannabinoids, signaling molecules produced in the body that share features with chemicals found in marijuana, can shut down genes needed for some pathogenic intestinal bacteria to colonize, ...
- What is post-viral fatigue syndrome, the condition affecting some COVID-19 survivors?on October 6, 2020 at 5:33 am
For many of us, becoming ill with a virus might put us on the couch for a week or two. It's frustrating, but after recovering we can generally get back to the things we're used to.
- Covid-19: What is post-viral fatigue syndrome, the condition affecting some coronavirus survivors?on October 5, 2020 at 10:55 pm
For some people, contracting a viral infection like Covid-19 can be life-altering. It can cause months, years or even a lifetime of debilitating symptoms that drastically reduce their quality of life.
- Synthetic Bio's lead candidate flunks irritable bowel study; shares down 42%on October 2, 2020 at 9:38 am
(NYSEMKT:SYN) plunges 42% premarket after announcing the results of a planned interim futility analysis of the investigator-sponsored Phase 2b clinical study of SYN-010 being conducted by Cedars-Sinai ...
- Synthetic Biologics cans phase 2 IBS trial deemed likely to failon October 2, 2020 at 7:25 am
Sinai Medical Center are pulling the plug on a phase 2b study in irritable bowel syndrome because it’s unlikely to hit its primary objective. Cedars-Sinai, the sponsor, will do a “comprehensive review ...
- Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patientson October 2, 2020 at 4:37 am
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal ("GI") diseases in ...
- Arena Pharmaceuticals Completes Full Enrollment of Olorinab Phase 2 CAPTIVATE Trial for Abdominal Pain in Irritable Bowel Syndromeon October 1, 2020 at 6:30 am
Arena Pharmaceuticals, Inc. today announced that it has completed full enrollment of the Phase 2 b CAPTIVATE trial evaluating olorinab, an investigational, oral, highly-selective, full agonist of the ...
- Seed Health will assemble a comprehensive taxonomic and functional dataset to investigate the role of gut metabolites in IBSon September 29, 2020 at 6:30 am
and placebo-controlled clinical trial to investigate the role of the gut microbiome in patients with Irritable Bowel Syndrome (IBS), as well as the impact of DS-01™ on both intestinal cells and ...
- FDA authorizes new IND to evaluate impact of multi-strain probiotic DS-01™ on gut microbiota of patients with IBSon September 29, 2020 at 6:00 am
FDA authorizes new IND to evaluate impact of multi-strain probiotic DS-01™ on gut microbiota of patients with IBS ...
- Irritable Bowel Syndrome Market Size and Share 2020 to 2025 Market Segmentationby Product Type Level, Industry Level, Analysis of COVID-19 Impacton September 27, 2020 at 9:57 pm
Final Report will add the analysis of the impact of COVID-19 on this industry." “Irritable Bowel Syndrome Market” ...
via Bing News